Telemos Capital has finalized a new investment partnership with Helios Global Group, marking the exit of the previous financial sponsor, NorthEdge. The strategic rationale for this transaction centers on a "global-platform" play, merging the target's technical operational depth in medical communications with the new sponsor's flexible capital and international expansion expertise. This transition effectively prepares the organization for its next stage of evolution, moving beyond its regional success to become a dominant global provider of integrated biopharma services. This operation allows the management team to execute a definitive structural expansion into new service lines and geographic territories, particularly in the North American market. By incorporating the group into a family-backed investment framework, the organization gains the stability required to harness innovative technologies and scale its internal infrastructure in alignment with its expanding client base. The maneuver optimizes the group's financial profile, facilitating further strategic add-on acquisitions following the successful integration of previous market access specialists. Ultimately, the partnership solidifies the group’s standing as a primary enabler of scientific narrative and health economic innovation, bridging the gap between clinical research and global market commercialization.

This transaction is part of the Business Services industry, which currently tracks an average EBITDA multiple of 11.3x since the beginning of 2026, 1.3% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.